David Owen Williams, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug-Eluting Stents | 13 | 2020 | 681 | 1.450 |
Why?
|
| Angioplasty, Balloon, Coronary | 17 | 2016 | 1725 | 1.400 |
Why?
|
| Coronary Restenosis | 7 | 2016 | 396 | 0.950 |
Why?
|
| Stents | 13 | 2016 | 3178 | 0.840 |
Why?
|
| Coronary Artery Disease | 11 | 2020 | 6403 | 0.800 |
Why?
|
| Coronary Artery Bypass | 10 | 2020 | 2188 | 0.720 |
Why?
|
| Myocardial Revascularization | 5 | 2020 | 790 | 0.710 |
Why?
|
| Cardiology | 3 | 2018 | 1656 | 0.710 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 6 | 2014 | 322 | 0.680 |
Why?
|
| Radial Artery | 1 | 2021 | 187 | 0.650 |
Why?
|
| Coronary Stenosis | 5 | 2011 | 794 | 0.530 |
Why?
|
| Coronary Disease | 5 | 2020 | 5912 | 0.460 |
Why?
|
| Coronary Occlusion | 1 | 2017 | 304 | 0.450 |
Why?
|
| Brachytherapy | 3 | 2016 | 1223 | 0.440 |
Why?
|
| Specialization | 1 | 2018 | 778 | 0.430 |
Why?
|
| Angioplasty, Balloon | 2 | 2008 | 589 | 0.390 |
Why?
|
| Career Choice | 1 | 2018 | 756 | 0.380 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 808 | 0.350 |
Why?
|
| Heart Diseases | 2 | 2014 | 2778 | 0.350 |
Why?
|
| Device Approval | 1 | 2012 | 163 | 0.350 |
Why?
|
| Biotechnology | 1 | 2012 | 281 | 0.340 |
Why?
|
| Equipment and Supplies | 1 | 2012 | 273 | 0.330 |
Why?
|
| Heart Valve Diseases | 1 | 2016 | 1028 | 0.310 |
Why?
|
| Thoracic Surgery | 1 | 2014 | 722 | 0.290 |
Why?
|
| Diabetic Angiopathies | 2 | 2010 | 803 | 0.290 |
Why?
|
| Myocardial Ischemia | 3 | 2020 | 2110 | 0.280 |
Why?
|
| Patient Selection | 2 | 2017 | 4237 | 0.280 |
Why?
|
| Carotid Artery Diseases | 1 | 2013 | 877 | 0.270 |
Why?
|
| Registries | 9 | 2014 | 8207 | 0.260 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2016 | 1553 | 0.260 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 2371 | 0.250 |
Why?
|
| Clinical Trials as Topic | 4 | 2013 | 7995 | 0.210 |
Why?
|
| Contrast Media | 1 | 2016 | 5305 | 0.210 |
Why?
|
| Catheterization | 1 | 2008 | 1428 | 0.210 |
Why?
|
| Treatment Outcome | 16 | 2021 | 64568 | 0.210 |
Why?
|
| Coronary Vessels | 1 | 2014 | 3095 | 0.200 |
Why?
|
| Prosthesis Design | 6 | 2016 | 2114 | 0.200 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2016 | 3621 | 0.190 |
Why?
|
| Biomedical Research | 1 | 2016 | 3426 | 0.180 |
Why?
|
| Diffusion of Innovation | 2 | 2016 | 729 | 0.160 |
Why?
|
| Job Description | 1 | 2018 | 59 | 0.150 |
Why?
|
| Stroke | 3 | 2015 | 9712 | 0.140 |
Why?
|
| Sirolimus | 3 | 2010 | 1533 | 0.130 |
Why?
|
| Coronary Angiography | 5 | 2020 | 4470 | 0.130 |
Why?
|
| Furosemide | 1 | 2016 | 170 | 0.130 |
Why?
|
| Metals | 4 | 2012 | 719 | 0.120 |
Why?
|
| Humans | 33 | 2021 | 760617 | 0.120 |
Why?
|
| Certification | 1 | 2018 | 418 | 0.120 |
Why?
|
| Forecasting | 2 | 2016 | 2924 | 0.100 |
Why?
|
| Paclitaxel | 2 | 2010 | 1730 | 0.100 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2012 | 186 | 0.100 |
Why?
|
| Patents as Topic | 1 | 2012 | 111 | 0.090 |
Why?
|
| Creatinine | 1 | 2016 | 1896 | 0.090 |
Why?
|
| Europe | 3 | 2012 | 3413 | 0.080 |
Why?
|
| Proportional Hazards Models | 6 | 2012 | 12447 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 3410 | 0.080 |
Why?
|
| Risk Assessment | 8 | 2017 | 23972 | 0.080 |
Why?
|
| Risk Factors | 7 | 2017 | 74115 | 0.080 |
Why?
|
| Severity of Illness Index | 6 | 2011 | 15828 | 0.070 |
Why?
|
| Heart Valve Prosthesis | 1 | 2016 | 1462 | 0.070 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 15498 | 0.070 |
Why?
|
| United States | 11 | 2014 | 72272 | 0.070 |
Why?
|
| Government Regulation | 1 | 2012 | 524 | 0.070 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2012 | 452 | 0.070 |
Why?
|
| Cardiovascular Agents | 2 | 2015 | 839 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 2849 | 0.070 |
Why?
|
| Hospital Mortality | 3 | 2012 | 5293 | 0.060 |
Why?
|
| Time Factors | 7 | 2012 | 39913 | 0.060 |
Why?
|
| Thrombosis | 4 | 2011 | 2943 | 0.060 |
Why?
|
| Curriculum | 1 | 2018 | 3738 | 0.060 |
Why?
|
| Myocardial Infarction | 9 | 2011 | 11459 | 0.060 |
Why?
|
| Diabetes Complications | 2 | 2008 | 1315 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 1661 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 3873 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2008 | 823 | 0.050 |
Why?
|
| Comorbidity | 3 | 2012 | 10505 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2009 | 991 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2018 | 4789 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2017 | 9311 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2020 | 6474 | 0.050 |
Why?
|
| Calcinosis | 1 | 2011 | 1469 | 0.050 |
Why?
|
| Canada | 2 | 2009 | 2118 | 0.050 |
Why?
|
| Warfarin | 1 | 2009 | 1477 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 39063 | 0.040 |
Why?
|
| Female | 15 | 2020 | 392148 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2002 | 794 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 1700 | 0.040 |
Why?
|
| Male | 14 | 2020 | 360358 | 0.040 |
Why?
|
| Middle Aged | 12 | 2020 | 220584 | 0.030 |
Why?
|
| Logistic Models | 3 | 2011 | 13245 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2008 | 2152 | 0.030 |
Why?
|
| Angina, Unstable | 1 | 2020 | 888 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2003 | 6807 | 0.030 |
Why?
|
| Aged | 10 | 2020 | 169042 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 3085 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2009 | 4785 | 0.030 |
Why?
|
| Insulin | 1 | 2008 | 6593 | 0.030 |
Why?
|
| Diabetes Mellitus | 2 | 2008 | 5835 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 58894 | 0.030 |
Why?
|
| Animals | 2 | 2016 | 168201 | 0.020 |
Why?
|
| Reoperation | 1 | 2002 | 4300 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2020 | 2326 | 0.020 |
Why?
|
| Atherectomy, Coronary | 1 | 2011 | 137 | 0.020 |
Why?
|
| Prospective Studies | 6 | 2011 | 54360 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2009 | 5031 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2003 | 4174 | 0.020 |
Why?
|
| Cineangiography | 1 | 2009 | 108 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 12043 | 0.020 |
Why?
|
| Coronary Thrombosis | 1 | 2011 | 440 | 0.020 |
Why?
|
| Survival Rate | 1 | 2002 | 12719 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 2 | 2008 | 1496 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2009 | 352 | 0.020 |
Why?
|
| New Zealand | 1 | 2008 | 358 | 0.020 |
Why?
|
| Product Labeling | 1 | 2008 | 76 | 0.020 |
Why?
|
| Retreatment | 1 | 2008 | 596 | 0.020 |
Why?
|
| Quality of Life | 2 | 2020 | 13347 | 0.020 |
Why?
|
| Observation | 1 | 2008 | 310 | 0.020 |
Why?
|
| Atrial Appendage | 1 | 2009 | 278 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 10199 | 0.020 |
Why?
|
| Australia | 1 | 2008 | 1248 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2014 | 80566 | 0.020 |
Why?
|
| Smoking | 2 | 2011 | 9050 | 0.010 |
Why?
|
| Propensity Score | 1 | 2011 | 1911 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2009 | 1085 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2009 | 2635 | 0.010 |
Why?
|
| Equipment Design | 1 | 2009 | 3501 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2002 | 41457 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2009 | 5239 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2011 | 5486 | 0.010 |
Why?
|
| Sex Factors | 1 | 2011 | 10548 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2008 | 10073 | 0.010 |
Why?
|
| Age Factors | 1 | 2011 | 18381 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 12334 | 0.010 |
Why?
|
| Hypertension | 1 | 2008 | 8529 | 0.000 |
Why?
|
| Adult | 1 | 2009 | 220969 | 0.000 |
Why?
|